Hydrocortisone Sodium Phosphate OH the Individual Container May Be Too Small to Bear All the Appro- Priate Labelling Information

Total Page:16

File Type:pdf, Size:1020Kb

Hydrocortisone Sodium Phosphate OH the Individual Container May Be Too Small to Bear All the Appro- Priate Labelling Information Formocortal/Hydrocortisone 1535 Halcinonide (BAN, USAN, rINN) ⊗ Preparations Hydrocortisone Butyrate (BANM, USAN, rINNM) ⊗ Alcinonide; Halcinonid; Halcinónida; Halcinonidum; Halsinonid; Proprietary Preparations (details are given in Part 3) Butirato de hidrocortisona; Cortisol Butyrate; Hidrokortizon Halsinonidi; SQ-18566. 21-Chloro-9α-fluoro-11β-hydroxy- Austria: Sicorten; Belg.: Sicorten†; Ger.: Sicorten†; Hong Kong: Si- Bütirat; Hydrocortisone, Butyrate d’; Hydrocortisoni Butiras. Hy- corten; Neth.: Sicorten†; Port.: Sicorten†; Spain: Sicorten; Switz.: Si- 16α,17α-isopropylidenedioxypregn-4-ene-3,20-dione. corten; Turk.: Sicorten. drocortisone 17α-butyrate. Гальцинонид Multi-ingredient: Ger.: Sicorten Plus; Hong Kong: Sicorten Plus†; Isra- Гидрокортизона Бутират el: Sicorten Plus†; Port.: Sicorten Plus†; Spain: Sicorten Plus; Switz.: Si- C24H32ClFO5 = 455.0. corten Plus; Venez.: Sicorten Plus†. C25H36O6 = 432.5. CAS — 3093-35-4. CAS — 13609-67-1. ATC — D07AD02. ATC — D07AB02. ATC Vet — QD07AD02. ATC Vet — QD07AB02. Hydrocortisone (BAN, rINN) ⊗ Pharmacopoeias. In Chin., Jpn, and US. Anti-inflammatory Hormone; Compound F; Cortisol; Hidrocor- O CH3 USP 31 (Hydrocortisone Butyrate). A white to practically Cl tisona; Hidrokortizon; Hidrokortizonas; Hydrocortisonum; Hy- white, practically odourless crystalline powder. Practically insol- CH H3C O 3 drokortison; Hydrokortisoni; Hydrokortyzon; 17-Hydroxycorti- uble in water; soluble in alcohol, in acetone, and in methyl alco- HO O costerone; NSC-10483. 11β,17α,21-Trihydroxypregn-4-ene- hol; freely soluble in chloroform; slightly soluble in ether. 3,20-dione. H3CH Гидрокортизон Hydrocortisone Cipionate (BANM, rINNM) ⊗ C H O = 362.5. FH 21 30 5 Cipionato de hidrocortisona; Cortisol Cypionate; Hydrocorti- CAS — 50-23-7. O sone, Cipionate d’; Hydrocortisone Cyclopentylpropionate; Hy- ATC — A01AC03; A07EA02; C05AA01; D07AA02; drocortisone Cypionate; Hydrocortisoni Cipionas. Hydrocorti- H02AB09; S01BA02; S02BA01. sone 21-(3-cyclopentylpropionate). Pharmacopoeias. In Chin. and US. USP 31 (Halcinonide). A white to off-white, odourless, crystal- ATC Vet — QA01AC03; QA07EA02; QC05AA01; Гидрокортизона Ципионат line powder. Insoluble in water and in hexanes; slightly soluble QD07AA02; QD07XA01; QH02AB09; QS01BA02; C H O = 486.6. in alcohol and in ether; soluble in acetone and in chloroform. QS01CB03; QS02BA01. 29 42 6 CAS — 508-99-6. Profile ATC — A01AC03; A07EA02; C05AA01; D07AA02; Halcinonide is a corticosteroid used topically for its glucocorti- O H02AB09; S01BA02; S02BA01. coid activity (p.1490) in the treatment of various skin disorders. OH It is usually used as a 0.1% cream, lotion, or ointment. ATC Vet — QA01AC03; QA07EA02; QC05AA01; H3C OH QD07AA02; QH02AB09; QS01BA02; QS02BA01. When applied topically, particularly to large areas, when the skin HO is broken, or under occlusive dressings, corticosteroids may be H CH absorbed in sufficient amounts to cause systemic effects 3 Hydrocortisone Hydrogen Succinate (p.1490). The effects of topical corticosteroids on the skin are (BANM, rINNM) ⊗ described on p.1492. For recommendations concerning the cor- HH rect use of corticosteroids on the skin, and a rough guide to the Cortisol Hemisuccinate; Hidrogenosuccinato de hidrocortisona; clinical potencies of topical corticosteroids, see p.1497. O Hidrokortizon-hidrogén-szukcinát; Hidrokortizono hemisukcina- tas; Hydrocortisone Hemisuccinate; Hydrocortisone, Hémisuc- Preparations Pharmacopoeias. In Chin., Eur. (see p.vii), Int., Jpn, and US. cinate d’; Hydrocortisone, hydrogénosuccinate d’; Hydrocorti- USP 31: Halcinonide Cream; Halcinonide Ointment; Halcinonide Topical Ph. Eur. 6.2 (Hydrocortisone). A white or almost white, crys- sone Succinate; Hydrocortisoni Hemisuccinas; Hydrocortisoni Solution. talline powder. It shows polymorphism. Practically insoluble in hydrogenosuccinas; Hydrokortison-hydrogen-sukcinát; Hy- Proprietary Preparations (details are given in Part 3) water; sparingly soluble in alcohol and in acetone; slightly solu- drokortisonivetysuksinaatti; Hydrokortisonvätesuccinat. Hydro- Austria: Halog; Braz.: Halog; Canad.: Halog; Cz.: Betacorton; Ger.: Ha- ble in dichloromethane. Protect from light. cortisone 21-(hydrogen succinate). log†; Hong Kong: Halog; India: Cortilate; Indon.: Halog; Ital.: Halciderm; USP 31 (Hydrocortisone). A white to practically white, odour- Mex.: Dermalog; Spain: Halog; Switz.: Betacortone; Turk.: Volog; UK: less, crystalline powder. Very slightly soluble in water and in Гидрокортизона Гемисукцинат Halciderm†; USA: Halog; Venez.: Halog. ether; soluble 1 in 40 of alcohol and 1 in 80 of acetone; slightly C25H34O8 = 462.5. Multi-ingredient: Cz.: Betacorton S; Betacorton U; Ger.: Halog Tri†; soluble in chloroform. Store at a temperature of 25°, excursions CAS — 2203-97-6 (anhydrous hydrocortisone hydrogen India: Cobederm-H; Cortilate-S; Ital.: Anfocort; Halciderm; Halciderm permitted between 15° and 30°. Combi; Mex.: Dermalog-C; Switz.: Betacortone; Betacortone S; Turk.: succinate); 83784-20-7 (hydrocortisone hydrogen succi- Betacorton; Venez.: Halcicomb; Halog. nate monohydrate). Hydrocortisone Acetate (BANM, rINNM) ⊗ ATC — A01AC03; A07EA02; C05AA01; D07AA02; Acetato de hidrocortisona; Cortisol Acetate; Hidrokortizon H02AB09; S01BA02; S02BA01. ATC Vet — QA01AC03; QA07EA02; QC05AA01; Halometasone (rINN) ⊗ Asetat; Hidrokortizon-acetát; Hidrokortizono acetatas; Hydro- cortisone, acétate d’; Hydrocortisoni acetas; Hydrokortisonace- QD07AA02; QH02AB09; QS01BA02; QS02BA01. C-48401-Ba; Halometason; Halometasona; Halométasone; tat; Hydrokortison-acetát; Hydrokortisoniasetaatti; Hydroko- Pharmacopoeias. In Eur. (see p.vii) and Jpn. US allows the Halometasoni; Halometasonum; Halometazon; Halomethasone. rtyzonu octan. Hydrocortisone 21-acetate. anhydrous form or the monohydrate. 2-Chloro-6α,9-difluoro-11β,17,21-trihydroxy-16α-methylpreg- Гидрокортизона Ацетат Ph. Eur. 6.2 (Hydrocortisone Hydrogen Succinate). A white or na-1,4-diene-3,20-dione. almost white, hygroscopic powder. Practically insoluble in wa- C H O = 404.5. Галометазон 23 32 6 ter; freely soluble in dehydrated alcohol and in acetone; dissolves CAS — 50-03-3. C H ClF O = 444.9. in dilute solutions of alkali carbonates and alkali hydroxides. 22 27 2 5 ATC — A01AC03; A07EA02; C05AA01; D07AA02; Store in airtight containers. Protect from light. CAS — 50629-82-8. H02AB09; S01BA02; S02BA01. USP 31 (Hydrocortisone Hemisuccinate). It contains one mole- ATC — D07AC12. ATC Vet — QA01AC03; QA07EA02; QC05AA01; cule of water of hydration or is anhydrous. Store in airtight con- ATC Vet — QD07AC12. QD07AA02; QH02AB09; QS01BA02; QS02BA01. tainers. NOTE. HCOR is a code approved by the BP 2008 for use on single unit doses of eye drops containing hydrocortisone acetate where Hydrocortisone Sodium Phosphate OH the individual container may be too small to bear all the appro- priate labelling information. (BANM, rINNM) ⊗ O Pharmacopoeias. In Chin., Eur. (see p.vii), Int., Jpn, US, and Cortisol Sodium Phosphate; Fosfato sódico de hidrocortisona; H H3C Hydrocortisone, Phosphate Sodique d’; Natrii Hydrocortisoni HO OH Viet. Ph. Eur. 6.2 (Hydrocortisone Acetate). A white or almost Phosphas. Hydrocortisone 21-(disodium orthophosphate). CH 3 white, crystalline powder. Practically insoluble in water; slightly H3C H Натрия Гидрокортизона Фосфат Cl H soluble in dehydrated alcohol and in dichloromethane. Protect from light. C H Na O P = 486.4. F H 21 29 2 8 USP 31 (Hydrocortisone Acetate). A white to practically white, CAS — 6000-74-4. O odourless, crystalline powder. Insoluble in water; soluble 1 in 230 of alcohol and 1 in 200 of chloroform. ATC — A01AC03; A07EA02; C05AA01; D07AA02; HF H02AB09; S01BA02; S02BA01. ATC Vet — QA01AC03; QA07EA02; QC05AA01; Hydrocortisone Buteprate (BANM, rINNM) ⊗ Profile QD07AA02; QH02AB09; QS01BA02; QS02BA01. Halometasone is a corticosteroid used topically for its glucocor- Buteprato de hidrocortisona; Hydrocortisone, Butéprate d’; Hy- Pharmacopoeias. In Br., Jpn, and US. ticoid activity (p.1490) in the treatment of various skin disorders. drocortisone Butyrate Propionate; Hydrocortisone Probutate BP 2008 (Hydrocortisone Sodium Phosphate). A white or al- It is usually used as a cream containing 0.05% of halometasone (USAN); Hydrocortisoni Butepras; TS-408. Hydrocortisone 17- most white, hygroscopic powder. Freely soluble in water; practi- monohydrate. butyrate 21-propionate. cally insoluble in dehydrated alcohol and in chloroform. A 0.5% When applied topically, particularly to large areas, when the skin Гидрокортизона Бутепрат solution in water has a pH of 7.5 to 9.0. Protect from light. is broken, or under occlusive dressings, corticosteroids may be USP 31 (Hydrocortisone Sodium Phosphate). A white to light C H O = 488.6. absorbed in sufficient amounts to cause systemic effects 28 40 7 yellow, odourless or practically odourless, exceedingly hygro- (p.1490). The effects of topical corticosteroids on the skin are CAS — 72590-77-3. scopic, powder. Soluble 1 in 1.5 of water; slightly soluble in al- described on p.1492. For recommendations concerning the cor- ATC — D07AB11. cohol; practically insoluble in chloroform, in dioxan, and in rect use of corticosteroids on the skin, see p.1497. ATC Vet — QD07AB11. ether. Store in airtight containers. The symbol † denotes a preparation no longer actively marketed The symbol ⊗ denotes a substance whose use may be restricted in certain sports (see p.vii) 1536 Corticosteroids Hydrocortisone Sodium Succinate um succinate esters is rapid, while absorption of ly to be less
Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • United States Patent (10) Patent No.: US 7,524,836 B2 Del Soldato (45) Date of Patent: Apr
    USOO7524836B2 (12) United States Patent (10) Patent No.: US 7,524,836 B2 Del Soldato (45) Date of Patent: Apr. 28, 2009 (54) NITROOXYDERIVATIVESTEROIDAL JP 58-045724 3, 1983 COMPOUNDS JP 5-39.261 2, 1992 JP 4-273892 9, 1992 (75) Inventor: Piero Del Soldato, Milan (IT) WO 98.15568 4f1998 OTHER PUBLICATIONS (73) Assignee: Nicox S.A., Paris (FR) English language abstract of JP 58-045724. (*) Notice: Subject to any disclaimer, the term of this English language abstract of JP4-273892. patent is extended or adjusted under 35 English language abstract of DE 19634793. U.S.C. 154(b) by 173 days. K. B. Schwarz, “Oxidative Sress During Viral Infection: A Review”. Free Radical Biology & Medicine, vol. 21, No. 5, 1996, pp. 641-649. Goodman & Gillman, “The Pharmacological Basis of Therapeutics'. (21) Appl. No.: 11/643,887 9" Edition, 1996, McGraw-Hill Health preffsions Division, pp. 1-1. 1459–1465 and 1474. (22) Filed: Dec. 22, 2006 Martindale, The Extraphamacopeia,30" Edition, 1993, pp. 712-723. O O Nenseter et al., “Paracetamol inhibits Copper Ion-Induced, AZO Com (65) Prior Publication Data pound-Initialed, and Mononuclear Cell-Mediated Oxidative Modifi US 2007/O142342 A1 June 21, 2007 cation of LDL', Arterioscierosis, Thombosis, and Vascular Biology, s vol. 15, No. 9, Sep. 1995, pp. 1338-1344. O O Baylis et al. “Chronic Blockade of Nitric Oxide Synthesis in the Rat Related U.S. Application Data Produces Syntemic Hypertension and Glomemerular Damage'. J. (62) Division of application No. 1 1/028, 198, filed on Jan. 4, Clin. Investigation, vol.90, 1992, pp.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Effect of Early Vasopressin Vs Norepinephrine On
    Protocol Number: CRO1888 VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic Shock PROTOCOL NUMBER: CRO1888 EudraCT NUMBER: 2011-005363-24 SPONSOR: Imperial College London FUNDER: National Institute for Health Research DEVELOPMENT PHASE: PHASE IV STUDY COORDINATION CENTRE: Imperial Clinical Trials Unit PROTOCOL Version & Date: Version 2.1, 02.08.2013 Property of: Dr Anthony Gordon May not be used, divulged or published without the consent of: Dr Anthony Gordon Confidential Final Version2.1, 02.08.2013 Page 1 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Study Management Group Chief Investigator: Dr Anthony Gordon Co-investigators: Dr Stephen Brett Prof Gavin Perkins Prof Deborah Ashby Statistician: Dr Alexina Mason Trial Management: Ms Neeraja Thirunavukkarasu Study Coordination Centre For general queries, supply of trial documentation, and collection of data, please contact: Study Coordinator: Ms Neeraja Thirunavukkarasu Address: ICU – 11N, Charing Cross Hospital, Fulham Palace Road London W6 8RF E-mail: [email protected] Clinical Queries Clinical queries should be directed to Ms Neeraja Thirunavukkarasu who will direct the query to the appropriate person Sponsor Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at: Joint Research Compliance Office 510, Lab block, 5th Floor Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 0203 311 0213 Fax: 0203 311 0203 Funder National Institute for Health Research – Research for Patient Benefit and Clinician Scientist award schemes This protocol describes the VANISH study and provides information about procedures for entering participants.
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,871.241 B2 Chou Et Al
    USOO8871241 B2 (12) United States Patent (10) Patent No.: US 8,871.241 B2 Chou et al. (45) Date of Patent: Oct. 28, 2014 (54) INJECTABLE SUSTAINED RELEASE 3,829,570 A 8, 1974 Heider et al. DELIVERY DEVICES 3,854,480 A 12/1974 Zaffaroni 3,896,819 A 7, 1975 Zaffaroni et al. 3,916,899 A 11/1975 Theeuwes et al. (75) Inventors: Kang-Jye Chou, Watertown, MA (US); 3,948,254 A 4, 1976 Zaffaroni Hong Guo, Belmont, MA (US); Paul 3,961,628 A 6, 1976 Arnold Ashton, Boston, MA (US); Robert W. 3,977.404 A 8, 1976 Theeuwes Shimizu, Acton, MA (US); David A. 3,980,463 A 9, 1976 Muramoto et al. Watson, Westwood, MA (US) 3,993,071 A 1 1/1976 Higuchi et al. 4,008,719 A 2f1977 Theeuwes et al. (73) Assignee: pSivida US, Inc., Watertown, MA (US) 4,014,334 A 3, 1977 Theeuwes et al. 4,014,335 A 3, 1977 Arnold 4,034,758 A 7, 1977 Theeuwes (*) Notice: Subject to any disclaimer, the term of this 4,036.227 A 7, 1977 Zaffaroni et al. patent is extended or adjusted under 35 4,077.407 A 3, 1978 Theeuwes et al. U.S.C. 154(b) by 1563 days. 4,111.201 A 9, 1978 Theeuwes 4,111,203 A 9, 1978 Theeuwes (21) Appl. No.: 10/714,549 (Continued) (22) Filed: Nov. 13, 2003 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data CA 2544460 A1 5, 2001 US 2004/O176341 A1 Sep. 9, 2004 CN 1200033.
    [Show full text]